Pfizer’s Manufacturing Cost-Cutting May Leave Little Capacity For Growth
Executive Summary
Following its restructuring, Pfizer's in-house manufacturing capacity will support approximately $48 billion in sales
You may also be interested in...
Pfizer Tasks “Established Products Unit” With Extending Life Of Mature Drugs
As Pfizer faces a future without several key blockbuster drugs, Lipitor among them, the company is setting out to extend the life of its mature franchises with the formation of a dedicated business unit for established brands
Pfizer Tasks “Established Products Unit” With Extending Life Of Mature Drugs
As Pfizer faces a future without several key blockbuster drugs, Lipitor among them, the company is setting out to extend the life of its mature franchises with the formation of a dedicated business unit for established brands
Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry